What’s in Aridis Pharmaceuticals Inc (NASDAQ:ARDS) After Decline in Shorted Shares?

October 2, 2018 - By Darrin Black

The stock of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) registered a decrease of 92.25% in short interest. ARDS’s total short interest was 2,000 shares in October as published by FINRA. Its down 92.25% from 25,800 shares, reported previously. With 32,000 shares average volume, it will take short sellers 0 days to cover their ARDS’s short positions. The short interest to Aridis Pharmaceuticals Inc’s float is 2.08%.

The stock increased 4.58% or $0.57 during the last trading session, reaching $13.02. About 920 shares traded. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) has 0.00% since October 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company has market cap of $105.51 million. The Company’s lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. It currently has negative earnings. The firm is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients.

More important recent Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) news were published by: Benzinga.com which released: “42 Stocks Moving In Monday’s Mid-Day Session” on September 24, 2018, also Streetinsider.com published article titled: “Maxim Group Starts Aridis Pharmaceuticals (ARDS) at Buy”, Benzinga.com published: “The Week Ahead: Nike Earnings, FDA Debates E-Cig Industry, SurveyMonkey IPOs” on September 24, 2018. More interesting news about Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) was released by: Seekingalpha.com and their article: “Aridis Pharmaceuticals issues additional broad patent for AR-201and AR-401” with publication date: September 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>